clinical trial · NCT07080125
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
Boehringer Ingelheim·—·active not recruiting·n = 2,000
Interstitial Lung DiseasesSystemic Sclerosis Associated Interstitial Lung DiseaseOfev®
brief summary
This post-approval registry study is planned to generate data to address remaining questions on long-term effectiveness and to better characterize longer term beneficial effects of Nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) in terms of survival, quality of life, pattern of disease progression as well as effectiveness and safety in the subgroup of patients with pulmonary hypertension.
started
Jun 17, 2025
primary completion
Dec 31, 2033
completion
Dec 31, 2033
last updated
Dec 8, 2025
official title
Non-interventional Post-authorization Effectiveness Study to Assess Long-term Outcomes of Nintedanib Treatment in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol